04 Aug, EOD - Indian

Nifty Midcap 100 57432.35 (1.40)

Nifty IT 35203.35 (1.60)

Nifty Next 50 66917.5 (1.09)

Nifty 50 24722.75 (0.64)

Nifty Pharma 22153.8 (0.65)

SENSEX 81018.72 (0.52)

Nifty Bank 55619.35 (0.00)

Nifty Smallcap 100 17893.4 (1.27)

04 Aug, EOD - Global

NIKKEI 225 40290.7 (-1.25)

HANG SENG 24733.46 (0.92)

S&P 6329.55 (1.13)

Login/Signup
Careers
LOGIN HERE
Cancel

companylogoConcord Drugs Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 538965 | NSE Symbol : | ISIN : INE858L01010 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
30-Jun-2025 03-Jul-2025 EGM Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/07/2025 inter alia to consider and approve various agenda items Outcome of Board meeting Intimation for Increase in Authorized capital (As Per BSE Announcement dated on 03.07.2025)
19-Jun-2025 27-Jun-2025 Preferential Issue Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/06/2025 inter alia to consider and approve issue of equity shares through preferential issue and any other matter with the permission of chair Out come of Board Meeting (As Per BSE Announcement Dated on: 27/06/2025)
16-May-2025 23-May-2025 Accounts Concord Drugs Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 inter alia to consider and approve Audited Results for Quarter and Financial Year ending March 31st 2025. Board of Directors have approved Audited Financial Results for Quarter and Year ending 31st March,2025 in Board Meeting held. (As Per BSE Announcement Dated on: 23/05/2025)
04-Mar-2025 17-Mar-2025 Preferential Issue Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/03/2025 inter alia to consider and approve Increase in Authorised Capital of the company Fund raising by way of preferential issue of shares and warrants etc and other items. Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/03/2025 ,inter alia, to consider and approve 1. Increase in Authorised Capital 2. Issue of shares on Preferential Allotment 3. Any other matter with the permission of chair. (As Per BSE Announcement Dated on: 13/03/2025) Outcome of Board Meeting (As Per BSE Announcement Dated on: 17/03/2025)
07-Jan-2025 11-Jan-2025 Quarterly Results Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/01/2025 inter alia to consider and approve Un-Audited Financial Results of 31st December 2024 Company has approved its financial results for quarter ended 31 December, 2024 in its Board Meeting held on 11 Janaury 2025. Outcome of Board Meeting (As per BSE Announcement Dated on 11/01/2025)
06-Nov-2024 13-Nov-2024 Quarterly Results Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Un-audited Financials for quarter ended 30th Sep 2024 Financial Results for Q2 ending 30 September 2024 (As Per Bse Announcement Dated on 13.11.2024)
02-Sep-2024 06-Sep-2024 Increase in Authorised Capital Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/09/2024 inter alia to consider and approve Increase in Authorized Capital Proposal for Issue of Preferential Issue of Shares Other business if any. Out Come of Board Meeting . (As Per BSE Announcement Dated on: 06/09/2024)
03-Aug-2024 09-Aug-2024 Quarterly Results Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve Concord Drugs Ltd has informed BSE that the meeting of the Board of directors Meeting is scheduled on 09th August 2024 for Approval of Unaudited(Standalone & Consolidated) Financial Results for 1st Quarter 2024 and to consider any other matter by permission of Chair Submission of Financial Results for Quarter ended 30.06.2024 Submission of financial results for year/quarter ended 31.03.2024 after rectification . (As Per BSE Announcement Dated on: 08/08/2024)
15-May-2024 30-May-2024 Accounts Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2024 inter alia to consider and approve Audited Financial results (standalone & Consolidated) for the Quarter ended 31.03.2024. The Board Meeting to be held on 25/05/2024 has been revised to 30/05/2024 The Board Meeting to be held on 25/05/2024 has been revised to 30/05/2024 (As Per BSE Annnouncement Dated on: 24/05/2024) Audited Results for Financial year 2023-2024 (As Per BSE Announcement Dated on 30.05.2024)
19-Mar-2024 19-Mar-2024 Change in Other Executives Appointment of Ms. Namratha Nagla (ACS-68979) as Company Secretary Cum Compliance Officer
06-Feb-2024 13-Feb-2024 Quarterly Results Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve Un-Audited financial results (Standalone and Consolidated) for the quarter ended 31.12.2023. Un-audited Financial Results (Standalone and Consolidated) for the Quarter ended 31* December, 2023. (As Per BSE Announcement dated on 13.02.2024)
07-Nov-2023 14-Nov-2023 Quarterly Results Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve Un-Audited financial results (Standalone and Consolidated) for the quarter and half year ended 30.09.2023. Un-Audited Financial Results (Both Standalone and Consolidated) for the quarter ended 30.09.2023 (As Per BSE Announcement Dated on 14/11/2023)
27-Oct-2023 27-Oct-2023 Conversion Outcome of Board Meeting held on 27.10.2023
12-Oct-2023 12-Oct-2023 Conversion Outcome of Board Meeting held on 12.10.2023
07-Sep-2023 07-Sep-2023 AGM Outcome of Board Meeting held on 07.09.2023
1 2 3 

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.
+91-22-25229720
+91-8657545825
>info@capitalmarket.com

For any Capital Market Website related queries mail to :
webdesk@capitalmarket.com

For Capital Market Magazine subscription queries :
subscription@capitalmarket.com

For Capital Market Online Product related queries :
financeshop@capitalmarket.com

To advertise on Capital Market Websites mail to :
advt@capitalmarket.com

To email Press Releases :
pressrelease@capitalmarket.com

Kindly note www.capitalmarket.com does not send any mobile SMS, whatsapp or twitter messages giving any kind of stock recommendations.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +